RxDoctor Payments Data

David Tillery, DO

Family Medicine · Lancaster, OHNPI 1346633740

Payments from drug & device makers

$4,629in general payments, 2019–2025

Across 190 payments — averaging $24.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$843
  • Lilly USA, LLC$333
  • Abbott$318
  • Novo Nordisk$285
  • Boehringer Ingelheim$221
  • Exact Sciences$221
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$4,629100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,629 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$57,522
Medicare patients
162
Services billed
661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide113$136,537
EliquisApixaban118$119,097
Trelegy ElliptaFluticasone/Umeclidin/Vilanter96$70,311
JardianceEmpagliflozin63$69,581
XareltoRivaroxaban48$44,708
FarxigaDapagliflozin Propanediol36$34,176
ProliaDenosumab16$27,493
MounjaroTirzepatide13$27,296
JanuviaSitagliptin Phosphate22$26,728
Breo ElliptaFluticasone/Vilanterol57$26,697
EntrestoSacubitril/Valsartan12$20,979
LinzessLinaclotide19$13,067
Spiriva RespimatTiotropium Bromide23$12,938
SymbicortBudesonide/Formoterol Fumarate31$8,771
Atorvastatin Calcium618$7,754

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$285$136,537113 claims
PfizerEliquis, Lyrica$120$126,192130 claims
GSKTrelegy Ellipta, Breo Ellipta$68$97,008153 claims
Boehringer IngelheimJardiance, Spiriva Respimat$221$82,51986 claims
Johnson & JohnsonXarelto$61$44,70848 claims
AstraZenecaFarxiga, Symbicort$843$42,94867 claims
AmgenProlia$203$27,49316 claims
Lilly USA, LLCMounjaro$333$27,29613 claims
MerckJanuvia$77$26,72822 claims
NovartisEntresto$109$20,97912 claims
AbbVieLinzess$195$13,06719 claims
Astellas Pharma US IncMyrbetriq$110$7,56111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Lancaster

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →